mmchren@itsa.ucsf.edu
(415) 221-4810, x2091 (Derm Svc)
(415) 751-3927 (fax)

Veteran's Affairs Medical Center, Division of Geriatrics, VAMC 190, San Francisco, CA 94121

Smith College, Northampton, MA, A.B., 1974, Biological Sciences
Yale University, New Haven, CT, M.D., 1978, Medicine
The Mount Sinai Hospital, New York, NY, 1979, Internal Medicine
Stanford University Hospital, Stanford, CA, 1982, Internal Medicine
University Hospitals of Cleveland, Cleveland, OH, 1989, Dermatology
University Hospitals of Cleveland, Cleveland, OH, 1991, Research fellowship, Clinical Epidemiology

Original Research (selected from 60 peer-reviewed publications)

Chren MM, Landefeld CS, Murray TH. Doctors, drug companies and gifts. JAMA 1989, 262:3448-3451.

Chren MM, Lazarus HM, Bickers DR. Landefeld CS. Rashes in immunocompromised cancer patients: The diagnostic yield of skin biopsy and its effects on therapy. Arch Dermatol, 1993; 129:175-81.

Chren MM, Landefeld CS. Physicians' behavior and their interactions with drug companies: A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 1994; 271:684-689.

Chren MM, Landefeld CS. A cost analysis of topical drug regimens for dermatophyte infections. JAMA 1994; 272:1922-1925.

Chren MM, Lazarus HM, Salata RA, CS Landefeld. Cultures of skin biopsy tissue from immunocompromised patients with cancer and rashes. Arch Dermatol 1995; 131:552-555.

Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996; 107; 707-713.

Chren MM, Lasek RJ, Quinn LM, Covinsky KE. Convergent and discriminant validity of a generic and a disease-specific instrument to measure quality of life in patients with skin disease. J Invest Dermatol 1997; 108:103-107.

Chren MM, Lasek, RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997;133:1433-1440.

Lasek RJ, Chren MM. The effects of acne vulgaris on the quality of life of adult dermatology patients. Arch Dermatol 1998; 134:454-458.

Polster AM, Lasek RJ, Quinn LM, Chren MM. Reports by patients and dermatologists of skin cancer preventive services provided in dermatology offices. Arch Dermatol 1998; 134:1095-98.

Covinsky K, Palmer RM, Counsell SR, Pine ZM, Walter LC, Chren MM. Functional status prior to hospitalization in acutely ill elders: Validity and clinical importance of retrospective reports. J Am Geriatr Soc 2000; 48:164-69.

Jones-Caballero M, Penas PF, Garcia-Diez A, Badia X, Chren MM. The Spanish version of Skindex-29. Cultural adaptation and preliminary evidence of validity and equivalence with the original American version. Int J Dermatol 2000; 39:907-912.

Pine ZM, Gurland B, Chren MM. Elders who report having slowed down: Evidence for the validity of a new way to inquire about preclinical functional decline. J Gerontol Med Sci 2000; 55A:M378-M383.

Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16, A brief quality-of-life measure for patients with skin diseases. Journal of Cutaneous Medicine and Surgery 2001; 5:105-10.

Mirmirani P, Maurer T, Berger T, Sands L, Chren MM. Skin-related quality of life in HIV-infected patients on highly active antiretroviral therapy. Journal of Cutaneous Medicine and Surgery 2002; 6:10-15.

Abeni D, Picardi A, Pasquini P, Melchi CF, Chren MM. Further evidence of the validity and reliability of Skindex-29: An Italian study on 2242 dermatological outpatients. Dermatology 2002; 204:43-49.

Pine ZM, Gurland B, Chren MM. Use of a cane for ambulation: marker and mitigator of impairment among elders who report no difficulty walking. J Amer Geriatric Soc 2002; 50: 263-8.

Chamlin SL, Frieden IJ, Williams ML, Chren MM. The effects of atopic dermatitis on young American children and their families. Pediatrics 2004; 114:607-11.

Chren MM, Sahay AP, Sands LP, Maddock L, Lindquist K, Bertenthal D, Bacchetti P. Variation in care for nonmelanoma skin cancer in a private practice and a Veterans Affairs clinic. Med Care 2004; 42:1019-26.

Asgari M, White E, Chren MM. Nonsteroidal anti-inflammatory drug use in the prevention and treatment of squamous cell carcinoma. Dermatol Surg. 2004 Oct;30(10):1335-42.

Chamlin SL, Mattson MS, Frieden IJ, Williams ML, Mancini AJ, Cella D, Chren MM. The price of pruritus: sleep disturbance and co-sleeping in atopic dermatitis. Arch Ped Adol Med 2005; 159:745-50.

Chamlin SL, Cella D, Frieden IJ, Williams ML, Mancini AJ, Lai JS, Chren MM. Development of the Childhood Atopic Dermatitis Impact Scale: initial validation of a quality-of-life measure for young children with atopic dermatitis and their families. J Invest Dermatol 2005; 125:1106-11.

Non-experimental articles

Chren MM. Dermatologic consultations--how can we know if we're worth it? Methodologic considerations for the critical assessment of medical interventions performed by physicians. Arch Dermatol 1994; 130:1052-1054.

Chren MM. Quality of care in dermatology: the state of (measuring) the art. (editorial) Arch Dermatol 1997; 133:1349-51.

Chren MM. Understanding research about quality of life and other health outcomes. J Cut Med Surg 1999; 3:312-6.

Chren MM. Giving 'scale' new meaning in dermatology Measurement matters.(editorial) Arch Dermatol 2000;136:788-90.

Chren MM. DoctorÕs orders: Re-thinking compliance in dermatology (editorial). Arch Dermatol 2002; 138:393-4.

Chren MM, Weinstock, MA. Conceptual issues in measuring the burden of skin diseases. J Investig Dermatol Symp Proc. 2004 Mar;9(2):97-100.

Chren MM. Measurement of vital signs for skin diseases. (editorial) J Invest Dermatol 2005; 125: viii-ix.

Chren MM. Determining the value of surgical therapies for basal cell carcinoma. Arch Dermatol 2006; 142:231-32.

12/7/06